Magazine Article | October 1, 2020

Companies To Watch: Osivax

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Advancing universal vaccines for flu, coronavirus, and other viral infections

SNAPSHOT

Osivax is developing universal vaccines for influenza, coronaviruses, and other infectious diseases such as malaria and human papillomavirus (HPV). Based on the company’s oligoDOM platform, the vaccines stimulate the immune system to produce CD-8 T cells that target the nucleoprotein (NP) produced by infected cells. The lead candidate vaccine for flu, coded OVX836, is an intramuscular form in Phase 2a development; an intranasal form is near the end of a Phase 1 trial. Preclinical studies have started on a coronavirus vaccine, which would include COVID-19. Partnerships are ongoing with an HPV prophylactic/therapeutic and a malaria vaccine in Phase 1 trials.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: